Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for voriconazole tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

According to IMS Health sales data for the 12 month period ending July 2015, the Vfend market achieved annual sales of approximately $91.4 million.

Glenmark’s current portfolio consists of 102 products authorised for distribution in the US marketplace and 63 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.